JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

The acquired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involved in BCR/ABL-negative myeloproliferative neoplasms (MPNs), but its effect on hematopoietic stem cells as a driver of disease emergence has been questioned. Therefore, we reinvestigated the role of endogenous expression of JAK2(V617F) on early steps of hematopoiesis as well as the effect of interferon-α (IFNα), which may target the JAK2(V617F) clone in humans by using knock-in mice with conditional expression of JAK2(V617F) in hematopoietic cells. These mice develop a MPN mimicking polycythemia vera with large amplification of myeloid mature and precursor cells, displaying erythroid endogenous growth and progressing to myelofibrosis. Interestingly, early hematopoietic compartments [Lin-, LSK, and SLAM (LSK/CD48-/CD150+)] increased with the age. Competitive repopulation assays demonstrated disease appearance and progressive overgrowth of myeloid, Lin-, LSK, and SLAM cells, but not lymphocytes, from a low number of engrafted JAK2(V617F) SLAM cells. Finally, IFNα treatment prevented disease development by specifically inhibiting JAK2(V617F) cells at an early stage of differentiation and eradicating disease-initiating cells. This study shows that JAK2(V617F) in mice amplifies not only late but also early hematopoietic cells, giving them a proliferative advantage through high cell cycling and low apoptosis that may sustain MPN emergence but is lost upon IFNα treatment.

[1]  A. M. de Bruin,et al.  Interferon-γ impairs proliferation of hematopoietic stem cells in mice. , 2013, Blood.

[2]  David A. Williams,et al.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. , 2013, Blood.

[3]  B. Ebert,et al.  Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. , 2012, Blood.

[4]  D. Yan,et al.  Critical requirement for Stat5 in a mouse model of polycythemia vera. , 2012, Blood.

[5]  A. Tefferi.  JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.

[6]  J. Berg,et al.  Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.

[7]  W. Vainchenker,et al.  New mutations and pathogenesis of myeloproliferative neoplasms. , 2011, Blood.

[8]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[9]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[10]  A. Green,et al.  Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. , 2011, Blood.

[11]  Takuya Matsunaga,et al.  R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. , 2011, Blood.

[12]  R. Hoffman,et al.  The renaissance of interferon therapy for the treatment of myeloid malignancies. , 2011, Blood.

[13]  J. Huber,et al.  Regulation of effector and memory T‐cell functions by type I interferon , 2011, Immunology.

[14]  P. Campbell,et al.  JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. , 2010, Blood.

[15]  R. Skoda.  JAK2 impairs stem cell function? , 2010, Blood.

[16]  W. Vainchenker,et al.  Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. , 2010, Blood.

[17]  Michael G. Kharas,et al.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.

[18]  E. Pronier,et al.  Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells , 2010, Leukemia.

[19]  F. Belardelli,et al.  Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity , 2010, Autoimmunity.

[20]  S. Fiering,et al.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.

[21]  R. Skoda.  JAK 2 impairs stem cell function ? , 2010 .

[22]  R. Levine,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[23]  T. Suda,et al.  Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion , 2009, Nature Medicine.

[24]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[25]  S. Chevret,et al.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.

[26]  W. Vainchenker,et al.  The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. , 2008, Blood.

[27]  Mamoru Ito,et al.  Interferon-2 b – induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes * , 2008 .

[28]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[29]  Lina A. Thoren,et al.  Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. , 2007, Cell stem cell.

[30]  W. Vainchenker,et al.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.

[31]  F. Schnütgen,et al.  Adopting the good reFLEXes when generating conditional alterations in the mouse genome , 2007, Transgenic Research.

[32]  R. V. van Etten,et al.  Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F , 2006, PloS one.

[33]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[34]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[35]  H. Sieburg,et al.  The GOD of Hematopoietic Stem Cells: A Clonal Diversity Model of the Stem Cell Compartment , 2006, Cell cycle.

[36]  P. Guttorp,et al.  The kinetics of clonal dominance in myeloproliferative disorders. , 2005, Blood.

[37]  S. Morrison,et al.  Supplemental Experimental Procedures , 2022 .

[38]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[39]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[40]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[41]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[42]  J. Segovia,et al.  Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. , 2004, Experimental hematology.

[43]  W. Alexander,et al.  SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. , 2004, Immunity.

[44]  K. Akashi,et al.  Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. , 2003, Blood.

[45]  D. Charnock-Jones,et al.  vavCre Transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages , 2002, Genesis.

[46]  A. W. Harris,et al.  Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. , 1999, Blood.

[47]  F.J. Sauvage,et al.  Role of c-mpl in early hematopoiesis. , 1998, Blood.

[48]  J. Visvader,et al.  Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. , 1998, Blood.

[49]  M. Cooper,et al.  Impairment of  T and B Cell Development by Treatment with a Type I Interferon , 1998, The Journal of experimental medicine.

[50]  W. Vainchenker,et al.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.

[51]  G. Rosenthal,et al.  Organ-specific hematopoietic changes induced by a recombinant human interferon-α in mice , 1990 .

[52]  G. Rosenthal,et al.  Organ-specific hematopoietic changes induced by a recombinant human interferon-alpha in mice. , 1990, Fundamental and applied toxicology : official journal of the Society of Toxicology.